{"drugs":["Tafluprost","Zioptan"],"mono":{"0":{"id":"930112-s-0","title":"Generic Names","mono":"Tafluprost"},"1":{"id":"930112-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930112-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Ocular hypertension - Raised intraocular pressure:<\/b> 1 drop TOPICALLY to affected eye(s) once daily in the evening; MAX use once daily<\/li><li><b>Open-angle glaucoma - Raised intraocular pressure:<\/b> 1 drop TOPICALLY to affected eye(s) once daily in the evening; MAX use once daily<\/li><\/ul>"},"1":{"id":"930112-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established "},"3":{"id":"930112-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Ocular hypertension - Raised intraocular pressure<\/li><li>Open-angle glaucoma - Raised intraocular pressure<\/li><\/ul>"}}},"3":{"id":"930112-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930112-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930112-s-3-10","title":"Precautions","mono":"<ul><li>intraocular inflammation, active, may be exacerbated<\/li><li>macular edema, including cystoid macular edema, has been reported with prostaglandin F2-alpha analogs; caution advised in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema<\/li><li>pigmentation of the iris, permanent, has been reported; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930112-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930112-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930112-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Neurologic:<\/b>Headache (6%)<\/li><li><b>Ophthalmic:<\/b>Conjunctival hyperemia (4% to 20%), Eye irritation (7%), Itching of eye (5%)<\/li><\/ul>"},"6":{"id":"930112-s-6","title":"Drug Name Info","sub":{"0":{"id":"930112-s-6-17","title":"US Trade Names","mono":"Zioptan<br\/>"},"2":{"id":"930112-s-6-19","title":"Class","mono":"<ul><li>Antiglaucoma<\/li><li>Prostaglandin<\/li><\/ul>"},"3":{"id":"930112-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930112-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930112-s-7","title":"Mechanism Of Action","mono":"Tafluprost is a prostaglandin analog and a selective FP prostanoid receptor agonist. The exact mechanism of action of tafluprost is unknown, but it is believed to decrease intraocular pressure by increasing uveoscleral outflow.<br\/>"},"8":{"id":"930112-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"930112-s-8-23","title":"Absorption","mono":"Tmax: 10 minutes <br\/>"},"2":{"id":"930112-s-8-25","title":"Metabolism","mono":"<ul><li>Eye: extensive<\/li><li>Tafluprost acid (major): active<\/li><\/ul>"},"3":{"id":"930112-s-8-26","title":"Excretion","mono":"concentrations below the level of quantification 30 minutes following administration <br\/>"}}},"9":{"id":"930112-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>provided in single-use containers, use immediately after opening, discard remainder<\/li><li>if more than 1 ophthalmic products is used, wait at least 5 minutes between administration of each product<\/li><\/ul>"},"10":{"id":"930112-s-10","title":"Monitoring","mono":"open angle glaucoma or ocular hypertension: reduction in intraocular pressure is indicative of efficacy<br\/>"},"11":{"id":"930112-s-11","title":"How Supplied","mono":"<b>Zioptan<\/b><br\/>Ophthalmic Solution: 0.0015 %<br\/>"},"13":{"id":"930112-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that drug may cause increased pigmentation to iris, eyelid, and eyelashes.<\/li><li>Warn patient that drug may cause eyelash changes (eg, increased length, color, thickness, shape, and number of lashes).<\/li><li>Drug may cause conjunctival hyperemia.<\/li><li>Instruct patient to immediately report signs\/symptoms of macular edema (eg, blurred vision, change in vision).<\/li><li>Counsel patient to only use drug once daily since more frequent dosing may decrease effectiveness.<\/li><li>Instruct patient to use solution immediately after container is opened and discard any remaining drug.<\/li><li>Advise patient using concomitant ophthalmic product to separate dosing of each product by 5 minutes.<\/li><\/ul>"}}}